Pre-made Pembrolizumab benchmark antibody ( Whole mAb, anti-PDCD1/PD-1 therapeutic antibody, Anti-CD279/PD1/SLEB2/hSLE1 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-435
Pre-Made Pembrolizumab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, and stomach cancer. It is given by slow injection into a vein.
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|Catalog No.||Package||List Price(In USD)||Discount off||Discount Price|
Size： 1mg | 10mg | 100mg
|Products Name (INN Index)||Pre-Made Pembrolizumab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Approved|
|100% SI Structure||5dk3:GF:BA/5ggs:CD:AB/5b8c:BA:HG:KJ:ED/5jxe:GF:DC|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||Aduro BioTech;AIO Studien gGmbH;Amgen;Augusta University;Bayer;BerGenBio;Big Ten Cancer Research Consortium;BioLineRx;Canadian Cancer Trials Group;Celgene Corporation;Columbia University;Dana-Farber Cancer Institute;DNAtrix;Duke University;Eisai Co Ltd;Eli Lilly;Emory University;Fox Chase Cancer Center;Genexine;Gilead Sciences;H. Lee Moffitt Cancer Center and Research Institute;Hoosier Cancer Research Network;Icahn School of Medicine at Mount Sinai;ImmunoGen;Incyte Corporation;Institut fuer Frauengesundheit;Institute of Cancer Research;M. D. Anderson Cancer Center;Massachusetts General Hospital;Mayo Clinic;Memorial Sloan-Kettering Cancer Center;Merck & Co;Merck Sharp & Dohme;National Cancer Center Hospital East;National Cancer Institute (France);National Cancer Institute (USA);Netherlands Cancer Institute;Northwestern University;NYU Langone Medical Center;Oslo University Hospital;Plexxikon;Providence Health & Services;Royal Marsden NHS Foundation Trust;Sarcoma Alliance for Research through Collaboration;Sellas Life Sciences Group;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;Spanish Breast Cancer Research Group;Syndax Pharmaceuticals;TG Therapeutics Inc;University Health Network;University of Alabama;University of Birmingham;University of California at Los Angeles;University of California at San Francisco;University of California San Diego;University of Colorado at Denver;University of Miami;University of Pittsburgh;University of Utah;University of Washington;Verastem Oncology;Wakayama Medical University;Washington University School of Medicine;Yale University;The Leukemia & Lymphoma Society|
|Conditions Approved||Cervical cancer;Colorectal cancer;Diffuse large B cell lymphoma;Gastric cancer;Head and neck cancer;Hodgkin's disease;Liver cancer;Malignant melanoma;Non-small cell lung cancer;Pancreatic cancer;Solid tumours;Urogenital cancer;Cancer;Merkel cell carcinoma;Renal cell carcinoma|
|Conditions Active||Small cell lung cancer;Bladder cancer;Breast cancer;Endometrial cancer;Fallopian tube cancer;Gastrointestinal cancer;Mesothelioma;Multiple myeloma;Nasopharyngeal cancer;Oesophageal cancer;Ovarian cancer;Peritoneal cancer;Prostate cancer;Squamous cell cancer;Acute myeloid leukaemia;Adenoid cystic carcinoma;Bone cancer;Brain metastases;Cholangiocarcinoma;Follicular lymphoma;Germ cell and embryonal neoplasms;Glioblastoma;Glioma;Inflammatory breast cancer;Liver metastases;Lymphoma;Meningioma;Myelodysplastic syndromes;Neuroendocrine tumours;Non-Hodgkin's lymphoma;Osteosarcoma;Penile cancer;Rectal cancer;Recurrent respiratory papillomatosis;Sarcoma;Soft tissue sarcoma;Thymoma;Thyroid cancer;Uveal melanoma;Chronic lymphocytic leukaemia;Haematological malignancies;Leiomyosarcoma;Mantle-cell lymphoma;Precursor cell lymphoblastic leukaemia-lymphoma;T-cell lymphoma;Gliosarcoma;Human papillomavirus infections|